Epidemiology of and antibacterial resistance in Gram-negative bloodstream infections among children with cancer and hematopoietic cell transplant recipients

Clicks: 17
ID: 327388
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #60 of 147 articles by views in journal of the pediatric infectious diseases society

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 147 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Abstract Background Bacteremia occurs in up to 30% of febrile neutropenic children receiving cancer therapy or hematopoietic cell transplant (HCT) and 14% of patients with non-neutropenic fever. Increasing antimicrobial resistance among Gram-negative pathogens is a challenge to providers, who seek to limit broad-spectrum antibacterial use while providing timely and effective empiric therapy. Experts recommend that the epidemiology of GN bloodstream infections (GNBSI) should be considered in developing guidelines for management of these infections, but there are few contemporary descriptions of GNBSI in this patient population. Methods This retrospective single-center cohort study included patients <22 years of age with cancer or HCT who had received immunosuppressive therapy within 3 months, and had a laboratory confirmed GNBSI diagnosed between 11/1/21 and 2/28/25. Demographic and clinical data were abstracted from patients’ electronic medical records. Results 239 episodes of GNB were identified in 153 patients. Fourteen infections (6%) were polymicrobial. The median age was 9.3 years (range, 0.3–21.9 years). Most patients were male (58%), white (73%) and had hematologic malignancies (59%) (Table 1). Of 82 HCT recipients, 62% experienced their infection within 100 days of transplant. A total of 164 (69%) of patients had >1 medical co-morbidity. Most patients were neutropenic at the onset of infection, with 78% having an absolute neutrophil count of <500 cells/L. Almost half had another concurrent infection. The most common isolated species were Escherichia coli (31%), Klebsiella pneumoniae (19%), and Enterobacter cloacae complex (13%) (Table 2). Among 218 isolates tested, 41% were cefepime nonsusceptible. Extended spectrum beta-lactamase expression was detected in 62% of 122 Enterbacterales tested;17 isolates (7%) were carbapenem-resistant. Overall, 104/212 (49%) of isolates were multidrug resistant (MDR). Patients required intensive care unit level care in 19% of episodes. A total of 40 (17%) had a focal complication of their infection, 33 patients (18%) had a second infection caused by the same bacterial species in the study period. The mean duration of hospitalization was 8 days (range1 to 178). Mortality at hospital discharge and 30-day all-cause mortality were 7% (17 patients). Only 5 patients, however, had active GNBSI at the time of their death. Conclusion In this study, GNBSI were associated with high morbidity and significant mortality. Resistance to cefepime and MDR was common and the majority of Enterobacterales expressed ESBL. Further studies are needed to assess the impact of antibacterial resistance on the outcomes of GNBSI and to inform treatment plans that enhance patient outcomes.
Reference Key
openalex_W7204669216 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal journal of the pediatric infectious diseases society
Year 2026
DOI
10.1093/jpids/piag070/piag070.065
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.